Home›Stock Screener›Solara Active Pharma Sciences

Solara Active Pharma Sciences Share Price Today | Stock Price & Solara Active Pharma Sciences Share Screener

SOLARA Pharmaceuticals
Live Share Price NSE
₹676.90
▼ -37.95 (-5.31%)
2026-10-05 00:00:00
Live Share Price BSE
₹676.50
▼ -39.50 (-5.52%)
2026-10-05 00:00:00

As of October 5, 2026, the live Solara Active Pharma Sciences share price (NSE: SOLARA) is ₹676.90 on NSE and ₹676.50 on BSE, down 5.31% from the previous close, with shares trading between ₹673.10 and ₹724.80 in today's trading session, and a 52-week range of ₹425.55–₹753.25. Check Solara Active Pharma Sciences 52-week for the annual price range and momentum. Use the Solara Active Pharma Sciences stock screener below to analyse P/E ratio, market cap, quarterly results, and more. See at what price today Solara Active Pharma Sciences opened, then compare its market price and price volume with top gainers and top losers on the exchange. Record your trades in TickJournal's free trading journal and track your portfolio performance.

Key Statistics and Valuation Ratios

Over the trailing twelve months the company reported revenue of ₹384 and net income of ₹16, with EBITDA of ₹65, an operating margin of 16.0% and a profit margin of 4.2%.

Solara Active Pharma Sciences Market Cap ₹3,577.67 Cr.
SOLARA P/E Ratio (TTM) -2233.94
Solara Active Pharma Sciences P/B Ratio 2.85
EPS (TTM) ₹-1.68
Dividend Yield -
Debt to Equity 0.63
SOLARA 52 Week High ₹753.25
Solara Active Pharma Sciences 52 Week Low ₹425.55
Operating Margin 16.00%
Profit Margin 4.17%
SOLARA Revenue (TTM) ₹384.00
EBITDA ₹65.00
Net Income ₹16.00
Total Assets ₹2,333.00
Total Equity ₹1,256.00

Solara Active Pharma Sciences Share Price Chart

Track the current stock price of Solara Active Pharma Sciences with an interactive chart. Analyse SOLARA share price trends, closing price, trading volume, historical performance, and volatility using live market data across different timeframes, from the last 30 days to the full record — the complete Solara Active Pharma Sciences stock quote in one place.

The quote of ₹676.90 sits between the 52-week low of ₹425.55 and the 52-week high of ₹753.25, and the latest session moved -5.31% from the previous close.

Solara Active Pharma Sciences Company Profile - Fundamental Screener

Screen Solara Active Pharma Sciences company fundamentals and business profile. Use our stock screener to analyze sector, industry, and key company metrics for SOLARA shares across the equity market and its stock price history, plus the wider market trend.

The company is classified under the Healthcare sector and the Pharmaceuticals industry, and it trades under ISIN INE624Z01016.

Company Details

Classification

Sector Healthcare
Industry Pharmaceuticals
Sub-Sector Pharmaceuticals
Segment E

Identifiers and Leadership

ISIN INE624Z01016

Solara Active Pharma Sciences Balance Sheet Screener

Screen SOLARA balance sheet fundamentals including assets, liabilities, and equity. Use our screener tool to analyze financial health and share price valuation metrics, then compare equity shares and the debt-to-equity rate against peers in the stock market.

For 2026, total assets were ₹2,333, up from ₹2,232 in 2025.

Latest statistics put total assets at ₹2,333 and shareholder funds at ₹1,256, with a leverage ratio of 0.63.

Item 2026 2025 2024 2023 2022 2021 2020 2019 2018

Assets

Total Assets 2,333 2,232 2,351 2,899 2,945 2,614 2,154 1,960 1,822
Current Assets 858 729 801 1,188 1,239 1,058 672 648 608
Fixed Assets 1,238 1,193 1,268 1,364 1,356 1,382 1,397 1,218 1,086

Liabilities

Total Liabilities 0 0 0 0 0 0 0 0 0
Current Liabilities 183 191 172 296 354 232 333 344 315
Non-Current Liabilities 0 0 0 0 0 0 0 0 0

Shareholders' Equity

Total Equity 1,256 1,097 937 1,502 1,527 1,593 1,090 960 769
Share Capital 45 40 36 36 36 36 27 26 25
Reserves & Surplus 1,208 1,054 898 1,464 1,489 1,553 963 826 739

Solara Active Pharma Sciences Income Statement Screener - Profit & Revenue Analysis

Screen Solara Active Pharma Sciences income statement and profit fundamentals. Analyze SOLARA quarterly results. Solara Active Pharma Sciences reports revenue growth, EBITDA, net profit margins, and EPS, and TickJournal's fundamental screener helps with stock evaluation and equity returns.

For 2026-Jun, revenue was ₹384 and net profit was ₹16, equal to earnings per unit of ₹3.52, at an operating margin of 16%.

In that period expenses were ₹320, interest cost ₹22 and tax ₹0. The next period listed, 2026-Mar, shows revenue of ₹393 and net profit of ₹10.

Item 2026-Jun 2026-Mar 2025-Dec 2025-Sept 2025-Jun 2025-Mar 2024-Dec 2024-Sept 2024-Jun 2024-Mar 2023-Dec 2023-Sept 2023-Jun 2023-Mar 2022-Dec

Revenue and Expenses

Revenue 384 393 349 314 320 279 302 347 364 301 212 426 354 385 402
Expenses 320 330 318 279 262 228 243 286 322 412 436 393 333 332 350

Operating Costs and Margins

EBITDA 65 63 31 35 58 51 59 62 43 -111 -224 34 21 53 52
Operating Profit % 16.00% 15.00% 9.00% 11.00% 18.00% 17.00% 19.00% 18.00% 12.00% -38.00% -106.00% 8.00% 5.00% 13.00% 11.00%
Depreciation 27 26 26 25 24 24 25 25 25 25 26 26 26 27 28
Interest 22 28 23 21 24 29 27 28 31 31 25 24 25 22 24

Profit and Earnings

Profit Before Tax 16 10 -17 -10 11 -2 8 8 -14 -167 -275 -17 -29 5 1
Tax 0 0 0 0 0 0 0 0 0 89 0 0 -10 1 0
Net Profit 16 10 -17 -10 11 -2 8 8 -14 -255 -275 -17 -19 4 0
EPS 3.52 2.20 -3.98 -2.36 2.46 -0.93 2.03 2.54 -3.50 -70.93 -72.07 -4.77 -5.43 1.05 0.12

Solara Active Pharma Sciences Cash Flow Screener - Liquidity Fundamentals

Screen SOLARA cash flow statements and liquidity fundamentals. Analyze operating, investing, and financing activities using our stock screener for share price strength and price trend assessment against the wider stock market and other stocks.

In 2026-March, operating activities generated ₹153, and net cash flow was an inflow of ₹1.

Over the same period, investing activities used ₹99 and financing activities used ₹54.

Item 2026-March 2025-March 2024-March 2023-March 2022-March 2021-March 2020-March 2019-March 2018-March

Cash from Operations and Investing

Operating Activities 153 213 109 156 -242 156 242 166 49
Investing Activities -99 -37 -4 -81 -243 -106 -359 -113 -86

Financing and Net Cash

Financing Activities -54 -181 -106 -113 334 93 97 -23 68
Net Cash Flow 1 -5 0 -38 -151 142 -20 30 32

Solara Active Pharma Sciences Shareholding Pattern Screener

See Solara Active Pharma Sciences shareholding pattern with promoter, FII, and DII holdings. Check Solara Active Pharma Sciences promoter holding and ownership changes for SOLARA on TickJournal, and see how institutional stock price moves affect the market.

In 2026-Jun, promoters held 41.93%, foreign institutions 11.52%, domestic institutions 3.74% and the public 25.84%, spread across 70,490 shareholders.

The shareholder count was 70,490 in 2026-Jun, compared with 70,037 in 2026-May.

Item 2026-Jun 2026-May 2026-Mar 2025-Mar 2025-Jun 2025-Sept 2025-Dec 2024-Mar

Promoter Holding

Promoter Holding 41.93% 42.00% 42.00% 37.94% 42.01% 42.01% 42.00% 30.49%

Institutional Investors

FII Holding 11.52% 11.33% 11.59% 14.63% 14.25% 13.58% 11.98% 15.80%
DII Holding 3.74% 3.78% 3.75% 2.61% 2.62% 2.69% 3.64% 2.97%

Government, Public and Others

Govt Holding 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Public Holding 25.84% 25.15% 25.03% 23.07% 23.47% 24.01% 24.63% 20.15%
Other Holding 16.97% 17.74% 17.63% 21.74% 17.63% 17.70% 17.74% 30.59%
Shareholder Count 70,490 70,037 70,400 75,791 74,334 72,479 71,920 73,912

Dividend Yield Screener - Share Price & Share Analysis

Check the dividend history with payout and yield data. View dividend details including ex-dates, the dividend rate, and amounts paid by Solara Active Pharma Sciences. Solara Active Pharma Sciences dividend yield can be compared with peers and other stocks in the market.

The latest dividend recorded was ₹0.00 per unit for 2026-March, a yield of 0.00%, compared with ₹0.00 for 2025-March.

Dividends are listed for 10 periods, with the three most recent payouts at ₹0.00, ₹0.00 and ₹0.00 per unit.

Period Dividend Per Share Dividend Yield
2026-March ₹0.00 0.00%
2025-March ₹0.00 0.00%
2024-March ₹0.00 0.00%
2023-March ₹3.00 0.88%
2022-March ₹0.00 0.00%
2021-March ₹7.00 1.14%
2020-March ₹2.00 0.16%
2019-March ₹5.00 1.22%
2018-March ₹0.00 0.00%
2017-March ₹0.00 0.00%

Solara Active Pharma Sciences Stock Index Membership - Nifty & Sensex

See which indices include Solara Active Pharma Sciences stock. Check SOLARA index membership in NIFTY 50, SENSEX, and other indices on TickJournal, and compare the Nifty trend with the broader market trend.

The company is listed in 3 indices, including BSE 1000.

Among the benchmarks tracked are BSE 1000, BSE INDEX BSE HC, BSE INDEX SMLCAP.

Complete Index List

BSE 1000
BSE INDEX BSE HC
BSE INDEX SMLCAP

Solara Active Pharma Sciences Market Events Screener - Corporate Actions

Get Solara Active Pharma Sciences corporate actions including splits, bonuses, and buybacks disclosed to the exchange. Check Solara Active Pharma Sciences stock events that may affect SOLARA share price, along with derivatives, futures and options activity and sector gainers.

14 corporate actions are listed, the most recent entry being Annual General Meeting dated September 18, 2026, with a record date of September 18, 2026.

It is followed by Quarterly Result Announcement dated July 23, 2026 and Quarterly Result Announcement dated May 15, 2026.

Announcement Date Record Date Event Type Information Price Impact
2026-09-18 2026-09-18 Annual General Meeting NA 18.04%
2026-07-23 2026-07-23 Quarterly Result Announcement NA -7.13%
2026-05-15 2026-05-15 Quarterly Result Announcement NA -1.55%
2026-02-06 2026-02-06 Quarterly Result Announcement NA 3.68%
2025-11-05 2025-11-05 Quarterly Result Announcement NA 4.97%
2025-09-25 2025-09-25 Annual General Meeting NA 1.99%
2025-07-25 2025-07-25 Quarterly Result Announcement NA -5.15%
2025-05-15 2025-05-15 Quarterly Result Announcement NA 19.48%
2025-01-24 2025-01-24 Quarterly Result Announcement NA 4.29%
2024-10-21 2024-10-21 Quarterly Result Announcement NA 8.18%
2024-09-20 2024-09-20 Annual General Meeting NA 6.04%
2024-05-15 2024-05-15 Rights 1:3 8.26%
2021-08-18 2021-08-20 Dividend ₹ 3.00 /share 5.36%
2017-03-25 2017-03-25 Change Of Name NA -

Solara Active Pharma Sciences Competitors Screener - Peer Stocks Comparison

Screen SOLARA competitors and compare share prices across peer stocks. Use our screener to analyze sector peers, fundamentals, and relative performance, from valuation and price target to the future price outlook, for better stock selection in a changing stock market.

The comparison table covers 10 companies in the Healthcare sector, shown with market capitalisation, P/E ratio, revenue, growth, net profit and RSI.

Company Market Cap P/E Ratio Revenue YoY Growth Net Profit RSI
Sun Pharmaceutical 447,476 36.44 61,674 12.69% 11,565 47.42
Divis Laboratories 250,363 86.51 11,067 13.95% 2,568 58.71
Torrent Pharmaceuticals 186,152 85.91 13,886 20.34% 2,138 48.14
Zydus Life Science 120,798 26.32 27,658 17.64% 5,026 61.81
Cipla 111,426 33.44 29,045 2.24% 3,870 44.03
Laurus Labs 106,838 99.70 6,868 22.01% 890 58.00
Mankind Pharma 105,107 48.73 14,636 14.85% 1,938 64.24
Dr Reddys Laboratories 104,492 32.05 35,059 3.90% 4,158 69.59
Aurobindo Pharma 97,682 26.36 34,145 5.56% 3,503 54.69
Lupin 93,829 16.99 29,039 26.75% 5,356 34.02

Solara Active Pharma Sciences Company Announcements - News & Reports Screener

Screen SOLARA latest company announcements and news updates. Filter stock news, results, and material events using our screener for share price impact analysis, and review the option chain for related stocks. Compare other stocks in the same sector.

20 recent announcements are listed, the latest dated October 4, 2026.

The next most recent announcements are dated October 2, 2026 and September 29, 2026.

Date Update Actions
2026-10-04 Intimation To Furnish Valid PAN KYC Details And Nomination By Shareholders Holding Physical Shares -
2026-10-02 Closure of Trading Window -
2026-09-29 Shareholder Meeting / Postal Ballot-Scrutinizers Report -
2026-09-18 Shareholder Meeting / Postal Ballot-Outcome of AGM -
2026-08-28 Intimation In Connection With The Receipt Of Rectification Order -
2026-08-26 Announcement under Regulation 30 (LODR)-Newspaper Publication -
2026-08-25 Business Responsibility and Sustainability Reporting (BRSR) -
2026-08-25 Reg. 34 (1) Annual Report. -
2026-08-25 Notice Of The Ninth Annual General Meeting -
2026-08-24 Announcement under Regulation 30 (LODR)-Newspaper Publication -
2026-08-19 Conversion Of Partly Paid-Up Rights Equity Shares Into Fully Paid-Up Equity Shares In Relation To The Rights Issue By The Company Upon Receipt Of The Call Monies As Applicable -
2026-08-18 Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS -
2026-08-07 Update With Respect To Our Intimation Dated July 23 2026 Regarding Appointment Of CIO And SMP Of The Company. -
2026-07-29 Announcement under Regulation 30 (LODR)-Earnings Call Transcript -
2026-07-24 Announcement under Regulation 30 (LODR)-Newspaper Publication -
2026-07-24 Submission Of Machine Readable Copy Of Financial Results For The Quarter Ended June 30 2026 -
2026-07-23 Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome -
2026-07-23 Announcement under Regulation 30 (LODR)-Monitoring Agency Report -
2026-07-23 Statement Of Deviation And Variation For Funds Raised Under Rights Issue For The Quarter Ended June 30 2026. -
2026-07-23 Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS -

Frequently Asked Questions

How is the company valued right now?

The current quote is ₹676.90, within a 52-week range of ₹425.55 to ₹753.25. The P/E ratio is -2233.94 and the P/B ratio is 2.85, with earnings per unit of ₹-1.68. Market capitalisation stands at ₹3,577.67 Cr. The company operates in the Healthcare sector, in the Pharmaceuticals industry, so compare these ratios with its sector peers in the table above.

About This Data

Quotes are sourced from the NSE and the BSE. Key statistics were last updated on October 6, 2026. This page covers 9 balance sheet periods, 15 income statement periods, 9 cash flow years and 8 shareholding periods. Information is provided for research and is not investment advice.